Treatment of CD19‐positive mixed phenotype acute leukemia with blinatumomab
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25317
Abstract: sion rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation. Pediatr Blood Cancer. 2012;58:61-65. 4. Brodsky MA, Rodeghier M, Sanger M, et al. Risk Factors for 30-Day… read more here.
Keywords: mixed phenotype; cd19 positive; positive mixed; treatment cd19 ... See more keywords
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-01056-6
Abstract: Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells) in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after an allotransplant remain unclear. Forty-three subjects with B-ALL relapsing post allotransplant… read more here.
Keywords: post allotransplant; cd19 positive; donor derived; cell ... See more keywords
Predictors of Rituximab Effect on Modified Rodnan Skin Score in Systemic Sclerosis: a machine learning analysis of the DESIRES trial.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac023
Abstract: OBJECTIVES The DESIRES trial showed that rituximab is effective in treating skin sclerosis in systemic sclerosis. However, which patient groups are likely to benefit from rituximab is unknown. METHODS We performed post-hoc analysis on prospective… read more here.
Keywords: cd19 positive; sclerosis; trial; cell counts ... See more keywords
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
Sign Up to like & getrecommendations! Published in 2022 at "Science Advances"
DOI: 10.1126/sciadv.abj2820
Abstract: A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It remains unclear if the long-term response is associated with the… read more here.
Keywords: cell; cd19 positive; positive relapse; relapse ... See more keywords
CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006302
Abstract: SARS-CoV-2 causes more severe COVID-19 disease in patients with hematologic diseases than in healthy individuals. 1-4 Reportedly, the acquisition of antibodies after SARS-CoV-2 vaccination in these patients is also inferior to that read more here.
Keywords: cd19 positive; vaccination; sars cov; lymphocyte count ... See more keywords
Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.23556
Abstract: Recent treatments of leukemias with T cells expressing chimeric antigen receptors (CARs) underline their impressive therapeutic potential but also their risk of severe side effects including cytokine release storms and tumor lysis syndrome. In case… read more here.
Keywords: retargeting unicar; unicar cells; tumor cells; cd19 positive ... See more keywords
CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1074740
Abstract: Access to commercial CD19 CAR-T cells remains limited even in wealthy countries like Canada due to clinical, logistical, and financial barriers related to centrally manufactured products. We created a non-commercial academic platform for end-to-end manufacturing… read more here.
Keywords: cd19 positive; hematologic malignancies; positive hematologic; car ... See more keywords